On Friday, Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was 8.56% up from the session before settling in for the closing price of $544.41. A 52-week range for MDGL has been $265.00 – $605.00.
A company in the Healthcare sector has dropped its sales by -32.06% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 50.62%. With a float of $20.63 million, this company’s outstanding shares have now reached $22.70 million.
Madrigal Pharmaceuticals Inc (MDGL) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Madrigal Pharmaceuticals Inc stocks. The insider ownership of Madrigal Pharmaceuticals Inc is 9.15%, while institutional ownership is 104.22%. The most recent insider transaction that took place on Dec 10 ’25, was worth 13,694,158. In this transaction Director of this company sold 24,800 shares at a rate of $552.18, taking the stock ownership to the 187,164 shares. Before that another transaction happened on Dec 10 ’25, when Company’s Director sold 18,650 for $552.15, making the entire transaction worth $10,297,573. This insider now owns 461,044 shares in total.
Madrigal Pharmaceuticals Inc (MDGL) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -2.71 earnings per share (EPS) during the time that was better than consensus figure (set at -4.12) by 1.41. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 50.62% per share during the next fiscal year.
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) Trading Performance Indicators
You can see what Madrigal Pharmaceuticals Inc (MDGL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -13.01, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach 1.77 in one year’s time.
Technical Analysis of Madrigal Pharmaceuticals Inc (MDGL)
Let’s dig in a bit further. During the last 5-days, its volume was 0.41 million. That was better than the volume of 0.37 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 38.77%.
During the past 100 days, Madrigal Pharmaceuticals Inc’s (MDGL) raw stochastic average was set at 95.56%, which indicates a significant increase from 87.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 21.75 in the past 14 days, which was higher than the 19.68 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $508.82, while its 200-day Moving Average is $382.95. However, in the short run, Madrigal Pharmaceuticals Inc’s stock first resistance to watch stands at $605.94. Second resistance stands at $620.87. The third major resistance level sits at $648.15. If the price goes on to break the first support level at $563.74, it is likely to go to the next support level at $536.46. Assuming the price breaks the second support level, the third support level stands at $521.53.
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) Key Stats
There are 22,711K outstanding shares of the company, which has a market capitalization of 13.42 billion. As of now, sales total 180,130 K while income totals -465,890 K. Its latest quarter income was 287,270 K while its last quarter net income were -114,190 K.
